First-in-human test of the study drug HW241045
Part of Lungs & breathing clinical trials.
This study is testing a new investigational drug called HW241045 in healthy volunteers. The main goal is to check how the drug is processed by the body and whether it is safe, which helps find the right dose for future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 45 years old.
- You must be in good general health, without serious chronic diseases (like heart, liver, or kidney problems).
- Your weight must be at least 50 kg (for men) or 45 kg (for women), and your body mass index (BMI) should be between 19 and 26.
- You must not have taken any drugs that affect liver metabolism in the last 30 days.
- You must not have significant allergies or a history of allergic reactions to multiple substances, and you must not be allergic to any component of the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.